GE Healthcare Signs a Worldwide Development and Commercialization Agreement with Theragnostics for Late Stage PSMA Diagnostic for Prostate Cancer

GE Healthcare’s Critical Care Suite AI Powered X-ray Device Receives FDA’s 510(k) Clearance to Identify Pneumothorax


  • The companies enter into a global commercialization agreement for new Prostate-Specific Membrane Antigen (PSMA) PET/CT imaging agent. GE Healthcare to take care of all pre-approval commercial preparations plus all subsequent commercial and distribution activities. Theragnostics to lead the development of the tracer, GalliProst (Gallium-68 (68Ga) diagnostic tracer) benefiting treatments for Prostate Cancer  
  • The companies will utilize their combined scientific, commercial and market access expertise for the launch. The process of detecting prostate cancer will initiate with a blood test or biopsy, after which patients are referred for PET/CT imaging allowing radiologists to see the tumor, lymph nodes and any metastasis for recommending better treatments
  • Theragnostics reported results of two clinical study that met its 1EPs and 2EPs showing one third of newly diagnosed prostate cancer patients and over 50% of patients with biochemically recurrent disease with 75% increment in patient management. TheragnosticsrPARP inhibitor THG-009 (I-123 labelled PARPi) first radiopharmaceutical therapy is expected to enter in clinical development in 2020

Click here to­ read full press release/ article | Ref: NewsWire | Image: Twitter